Ayala Pharmaceuticals Inc (ADXS)

[ubmmg]

JS wrote:

You clearly never read the PR.

Yes, I did read the PR. Very carefully. Although I hold only a GED in English, I understand you were probably referring to the following statement form the RP:
snip:

The withdrawal of this application does not impact the ongoing clinical trials of axalimogene filolisbac. As previously communicated, Advaxis is actively seeking a partner to support the late-stage cervical cancer program.

If so, let me clarify why Ken has virtually shelved AXAL altogether. Ken stated that EMA app withdrawal has no impact on an ongoing Aim2Cerv trial. That would have been acceptable statement had he not stated before that he planned to shelve Aim2cerv trial soon if there are no takers. He suggested he'd update us on the status of the CT during the next conference call. That was over a month ago. Now, if he knew he'd be able to partner Aim2Cerv within two more months, his obvious move would have been to package entire cervical program (AXAL+Adjuvant) and sell to the highest bidder with an EMA application/rights included. That would be a very logical thing to attempt. Instead, he pulls the application. Why? He could not buy more time with the EMA to allow the negotiations to come to fruition? You know very well that there is no restarting that EMA application from this control point. It all has to be restarted with a resubmission if that ever to occur.
Interpret however you want but Ken just killed entire AXAL platform. How shameful!